| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JC.2006-0305 |
| P698 | PubMed publication ID | 16868048 |
| P50 | author | Neal Fedarko | Q42666390 |
| Mohd Shazli Draman Yusoff | Q59615825 | ||
| P2093 | author name string | Daniel L Koller | |
| Tobias E Larsson | |||
| Bhaskar Dasgupta | |||
| Alka Jain | |||
| Kenneth E White | |||
| Holly J Garringer | |||
| Niamh Conlon | |||
| Corinne Fisher | |||
| Michael J Cullen | |||
| Siobhan I Davis | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4037-4042 | |
| P577 | publication date | 2006-07-25 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis | |
| P478 | volume | 91 |
| Q35783146 | A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells |
| Q35925637 | A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis |
| Q28482201 | A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis |
| Q37210780 | Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression |
| Q40478618 | Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. |
| Q37824821 | Clinical practice. Fibroblast growth factor (FGF)23: a new hormone |
| Q61831294 | Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations |
| Q41832467 | Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia |
| Q38725971 | Dietary Phosphorus Intake and the Kidney. |
| Q35590824 | Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis |
| Q34069277 | Differential response of idiopathic sporadic tumoral calcinosis to bisphosphonates |
| Q24653541 | FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? |
| Q37327002 | Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis |
| Q35203191 | Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification |
| Q36756061 | Fibroblast growth factor 23 and bone mineralisation |
| Q38353574 | GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity |
| Q39118846 | Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics |
| Q92358438 | Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Anti-Interleukin-1 Treatments |
| Q64235821 | Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in Gene: Experience from Southern Turkey |
| Q95840891 | Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management |
| Q89161363 | Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature |
| Q38345898 | Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action |
| Q35533372 | Hyperphosphatemic familial tumoral calcinosis: odontostomatologic management and pathological features. |
| Q57216982 | Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms |
| Q34069793 | Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis |
| Q37384718 | Latest findings in phosphate homeostasis |
| Q34273172 | Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature |
| Q92563543 | Mendelian Randomization Analysis Reveals a Causal Influence of Circulating Sclerostin Levels on Bone Mineral Density and Fractures |
| Q26827280 | Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho) |
| Q36956055 | Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis |
| Q33660188 | Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome |
| Q34147642 | Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium |
| Q83469034 | Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis |
| Q37559361 | Overview of the FGF23-Klotho axis |
| Q41646281 | Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome |
| Q34631794 | Recent advances in renal phosphate handling |
| Q37783496 | Reciprocal Control of 1,25-Dihydroxyvitamin D and FGF23 Formation Involving the FGF23/Klotho System |
| Q92889691 | Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF |
| Q35151453 | Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism |
| Q37095085 | Renal phosphate handling: Physiology |
| Q93180147 | The FGF metabolic axis |
| Q24625902 | The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis |
| Q93222971 | The Klotho proteins in health and disease |
| Q36860289 | The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis |
| Q37000627 | The lectin domain of the polypeptide GalNAc transferase family of glycosyltransferases (ppGalNAc Ts) acts as a switch directing glycopeptide substrate glycosylation in an N- or C-terminal direction, further controlling mucin type O-glycosylation |
| Q37771349 | The phosphate regulating hormone fibroblast growth factor-23. |
| Q36832542 | Tumoral calcinosis: new insights for the rheumatologist into a familial crystal deposition disease |
| Q28292466 | Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis |
Search more.